|
|
Persistent use of "false" cell lines.
by Marc Lacroix
InTextoResearch, Baelen, Wallonia, Belgium
Now in International Journal of Cancer, 122(1):1-4 (2008)
http://www3.interscience.wiley.com/cgi-bin/abstract/116834083/ABSTRACT
Summary
Quote: From HeLa, and its multiple identities, to MDA-MB-435, erroneously and
widely used as breast cancer cells, the history of cancer cell lines
is rich in misidentification and cross-contamination events. Despite
the fact that these problems were regularly signaled during the last
decades, many actors of research still seem to ignore them. A never-
ending story? Solutions exist, notably based on recent technical
advances in cell line authentication (short tandem repeat analysis).
However, a collaborative action involving users of cell lines, cell
banks, journals and funding agencies is needed to achieve success.
"False" cell lines mentioned:
Chang Liver, Girardi Heart, Hep2 (or Hep-2), INT407 (or INT-407, or
Intestine 407), J111, KB, L132, MT-1 (or MT1), NCTC2544, WISH, Wong-
Kilbourne, RPMI-8402 (or RPMI8402), IM-9 (or IM9), HBL-100 (or
HBL100), TSU-Pr1 (or TSUPr1), ECV-304 (or ECV304), EJ138, EJ-1 (or
EJ1), PPC-1 (or PPC1), ALVA-31 (or ALVA31), ALVA-41 (or ALVA41), SK-N-
MC, DAMI, HS-Sultan, ARH-77 (or ARH77), WiDr, SNB-19 (or SNB19), U251,
MCF-7ADR (re-designated NCI/ADR-RES), MDA-MB-435 (or MDA-MB-435S, or
MDA-MB435, or MDA-435) |
|
|
